Key result
Decades of dedicated efforts on clinical and technological aspects of mechanical circulatory support devices have led to their widespread success and acceptance for treating advanced heart failure.
Mechanical circulatory support devices have evolved significantly and are widely accepted for the treatment of advanced heart failure.
Answers are grounded in this paper and cite their sources.
Supports MCS acceptance in advanced HF; leaves open optimal selection, timing, and durability in broader populations.
Cardiovascular diseases and heart failure (HF) remain one of the major causes of worldwide mortality. According to the American Heart Association, 85.6 million adults in the US suffer from cardiovascular diseases, out of which 5.7 million are living with HF (1). Decades of dedicated efforts on clinical as well as technological aspects of mechanical circulatory support (MCS) devices have led to their widespread success and acceptance for the treatment of advanced HF.
No takes yet. Share an insight, caveat, or question.
Chatterjee et al. (2018) conducted a review in Cardiovascular diseases and heart failure. Mechanical circulatory support (MCS) was evaluated. Decades of dedicated efforts on clinical and technological aspects of mechanical circulatory support devices have led to their widespread success and acceptance for treating advanced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: